Recombinant Human LAG-3 Fc Chimera Protein, CF Summary
Product Specifications
| Human LAG-3 (Leu23-Leu450) Accession # P18627 |
IEGRMD | Human IgG1 (Pro100-Lys330) |
| N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
2319-L3
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. Reconstitute 30 minutes prior to use with minimal agitation. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: LAG-3
LAG-3 (Lymphocyte activation gene-3), designated CD223, is a 70 kDa type I transmembrane protein that is a member of the immunoglobulin superfamily (IgSF) (1, 2). LAG-3 shares approximately 20% amino acid sequence homology with CD4, but has similar structure and binds to MHC class II with higher affinity, providing negative regulation of T cell receptor signaling (1, 2). Human LAG-3 cDNA encodes 525 amino acids (aa) that include a 28 aa signal sequence, a 422 aa extracellular domain (ECD) with four Ig-like domains, a transmembrane region and a highly charged cytoplasmic region. Within the ECD, human LAG-3 shares 70%, 67%, 76%, and 73% aa sequence identity with mouse, rat, porcine, and bovine LAG-3, respectively. LAG-3 is expressed on activated CD4+ and CD8+ T cells, NK cells, and plasmacytoid dendritic cells (pDC), but not on resting T cells (1-3). LAG-3 on activated CD4+CD25+ Treg cells plays a role in their suppressive activity (4). LAG-3 limits the expansion of activated T cells and pDC in response to selected stimuli (3-5). A soluble 54 kDa form, sLAG-3, can be shed by metalloproteinases ADAM10 and TACE/ADAM17 (6, 7). While monomeric sLAG-3 itself may be inactive, shedding allows for normal T cell activation by removing negative regulation (7). Binding of a homodimerized sLAG-3/Ig fusion protein to MHC class II molecules induces maturation of immature DC, and secretion of cytokines such as IFN-gamma and TNF-alpha by type 1 cytotoxic CD8+ T cells and NK cells (8, 9). sLAG-3/Ig has been used as a potential adjuvant to stimulate a cytotoxic anti-cancer immune response (9, 10). In mice, deletion of LAG-3 and another negative regulator, PD-1, facilitates anti-cancer response but also blocks self-tolerance and increases susceptibility to autoimmune diseases (11, 12). In humans, antibody-mediated down‑regulation of LAG-3 and PD-1 allows more effective control of chronic malaria, while in NOD (non‑obese diabetic) mice, deletion of LAG-3 alone accelerates diabetes (12-14).
- Triebel, F. et al. (1990) J. Exp. Med. 171:1393.
- Baixeras, E. et al. (1992) J. Exp. Med 176:327.
- Workman, C.J. et al. (2004) J. Immunol. 172:5450.
- Huang, C.T. et al. (2004) Immunity 21:503.
- Workman, C.J. et al. (2009) J. Immunol. 182:1885.
- Li, N. et al. (2004) J. Immunol. 173:6806.
- Li, N. et al. (2007) EMBO J. 26:494.
- Andreae, S. et al. (2003) Blood 102:2130.
- Brignone, C. et al. (2007) J. Immunol. 179:4202.
- Brignone, C. et al. (2010) J. Transl. Med. 8:71.
- Woo, S.R. et al. (2011) Cancer Res. 72:917.
- Okazaki, T. et al. (2011) J. Exp. Med. 208:395.
- Bettini, M. et al. (2011) J. Immunol. 187:3493.
- Butler, N.S. et al. (2012) Nat. Immunol. 13:188.
Citations for Recombinant Human LAG-3 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
6
Citations: Showing 1 - 6
Filter your results:
Filter by:
-
A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies
Authors: Manna, L;Rapuano Lembo, R;Yoshioka, A;Nakamura, K;Passariello, M;De Lorenzo, C;
Cancers
Species: Human
Sample Types: Antibody
Applications: Bioassay -
Lymphocyte activation gene 3 is increased and affects cytokine production in rheumatoid arthritis
Authors: Pedersen, JM;Hansen, AS;Skejø, C;Juul-Madsen, K;Junker, P;Hørslev-Petersen, K;Hetland, ML;Stengaard-Pedersen, K;Østergaard, M;Møller, BK;Dreyer, L;Hauge, EM;Hvid, M;Greisen, S;Deleuran, B;
Arthritis research & therapy
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
HIV-1 Nef-mediated downregulation of CD155 results in viral restriction by KIR2DL5+ NK cells
Authors: P Fittje, A Hœlzemer, WF Garcia-Bel, S Vollmers, A Niehrs, K Hagemann, G Martrus, C Körner, F Kirchhoff, D Sauter, M Altfeld
Oncogene, 2022-06-24;18(6):e1010572.
Species: Human
Sample Types: Recombinant Proteins
Applications: Bioassay -
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
Authors: CJ Edwards, A Sette, C Cox, B Di Fiore, C Wyre, D Sydoruk, D Yadin, P Hayes, S Stelter, PD Bartlett, M Zuazo, MJ Garcia-Gra, G Benedetti, S Fiaska, NR Birkett, Y Teng, C Enever, H Arasanz, A Bocanegra, L Chocarro, G Fernandez, R Vera, B Archer, I Osuch, M Lewandowsk, YM Surani, G Kochan, D Escors, J Legg, AJ Pierce
British Journal of Cancer, 2021-12-30;0(0):.
Species: Human
Sample Types: Protein
Applications: Bioassay -
Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults
Authors: A Weinberg, J Canniff, N Rouphael, A Mehta, M Mulligan, JA Whitaker, MJ Levin
J. Immunol., 2017-06-12;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects.
Authors: Tian X, Zhang A, Qiu C, Wang W, Yang Y, Qiu C, Liu A, Zhu L, Yuan S, Hu H, Wang W, Wei Q, Zhang X, Xu J
J Immunol, 2015-03-16;194(8):3873-82.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human LAG-3 Fc Chimera Protein, CF
Average Rating: 5 (Based on 4 Reviews)
Have you used Recombinant Human LAG-3 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Yeast scFv that bind to LAG-3-Fc are in the upper right quadrant. The expected number of binders was observed and were later confirmed to be true LAG-3 binders.
